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Abstract
Epidemiological studies suggest that individuals with comorbid conditions including diabe-
tes, chronic lung, inflammatory and vascular disease, are at higher risk of adverse COVID-
19 outcomes. Genome-wide association studies have identified several loci associated with
increased susceptibility and severity for COVID-19. However, it is not clear whether these
associations are genetically determined or not. We used a Phenome-Wide Association
(PheWAS) approach to investigate the role of genetically determined COVID-19 susceptibil-
ity on disease related outcomes. PheWAS analyses were performed in order to identify traits
and diseases related to COVID-19 susceptibility and severity, evaluated through a predic-
tive COVID-19 risk score. We utilised phenotypic data in up to 400,000 individuals from the
UK Biobank, including Hospital Episode Statistics and General Practice data. We identified
a spectrum of associations between both genetically determined COVID-19 susceptibility
and severity with a number of traits. COVID-19 risk was associated with increased risk for
phlebitis and thrombophlebitis (OR = 1.11, p = 5.36e-08). We also identified significant sig-
nals between COVID-19 susceptibility with blood clots in the leg (OR = 1.1, p = 1.66e-16)
and with increased risk for blood clots in the lung (OR = 1.12, p = 1.45 e-10). Our study identi-
fies significant association of genetically determined COVID-19 with increased blood clot
events in leg and lungs. The reported associations between both COVID-19 susceptibility
and severity and other diseases adds to the identification and stratification of individuals at
increased risk, adverse outcomes and long-term effects.
Introduction
Corona Virus Disease 2019 (COVID-19) pertains to the disease caused by the virus SARS--
CoV-2 -severe acute respiratory syndrome coronavirus 2. This RNA virus belongs to a family
of coronaviruses that includes Middle East Respiratory Syndrome (MERS) and Severe Acute
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Respiratory Syndrome (SARS) [1]. COVID-19 was declared a pandemic by the WHO in
March 2020, and as of the 16th of April 2021, there have been 139,802,523 confirmed cases
documented in 219 countries [2].
Upon SARS-CoV-2 infection, typical symptoms include dry cough, fever, and loss of smell
and/or taste. However, the presentation of infection can range from asymptomatic to critical
illness which has led to categorisation of disease based on severity of symptoms. One definition
of severe COVID-19 is the need for admission to an intensive care unit and need for a ventila-
tor/supplementary oxygen which is less likely in mild to moderate COVID-19. The need for
hospitalisation is mainly due to infection of the lower respiratory tract and therefore inflam-
mation of lung alveoli, also known as pneumonia. This can lead to acute respiratory distress
syndrome (ARDS), sepsis and multi-organ failure which are some of the main causes of mor-
tality in COVID patients [3]. Aside from classifying severity of disease based on symptoms,
histopathological differences can also be used for classification purposes. For example, it has
been suggested that the formation of hyaline membranes, due to lack of surfactant leading to
alveolar collapse, are characteristic of pneumonia and therefore of severe COVID-19 [3].
The development of severe COVID is attributed to a dysregulated immune response char-
acterised by a cytokine storm, a severe and sustained activation of the inflammatory pathway
mediated by overexpression of cytokines [4]. Cytokines usually act as a signal for innate
immune cells, such as neutrophils and macrophages, to move to the site of infection. However,
when this is inappropriately sustained, the increased vascular permeability can lead to pulmo-
nary consolidation and other lung tissue injury. In addition to accumulation of pulmonary
exudates, the signalling cascade can result in apoptosis of lung epithelial cells which can lead to
the complication of ARDS since oxygen transfer is severely impaired. Studies have reported a
correlation of higher levels of pro-inflammatory cytokines (e.g. IL-6) and inflammatory mark-
ers (e.g. C-reactive protein (CRP)) with more severe clinical presentations [3]. There is also
evidence that type 1 interferon, an antiviral defence, is suppressed during the initial phase of
the disease, which promotes the over-activity of the inflammatory pathway underlying disease
severity [5]. The combination of low interferon levels and high pro-inflammatory cytokines is
what indicates the dysregulated innate immune response to COVID-19.
Following genome-wide association studies (GWAS) of susceptibility to severe COVID-19
infection, Mendelian Randomisation (MR) can then be used for causal inference of the role of
a specific variant or risk factor. The outputs of such analyses could serve as guide in clinical tri-
als aiming to repurpose existing medications for effective COVID-19 management. Baricitinib
is an example of an anti-inflammatory rheumatoid arthritis drug that has been repurposed to
help buffer the cytokine storm that leads to lung injury [6]. Furthermore, evidence of under
expression of IFNAR2, which encodes the receptor of interferon, amongst severe COVID-19
patients has led to clinical trials of interferons to reduce mortality rate [4]. In addition, geno-
mic analyses could reveal new therapeutic targets for drug development. 3CLpro, PLpro and
RdRp, the main enzymes responsible for SARS-COV-2 replication using host machinery,
emerged as potential therapeutic targets aids such as therapy with monoclonal antibodies
[7, 8].
GWAS have identified several loci associated with increased susceptibility to COVID-19
infection and severe disease [9]. The underlying genes of these association signals can be
broadly divided into underactive genes that enable viral replication and overactive genes that
result in pulmonary inflammation and the symptoms of severe COVID-19. The most promi-
nent findings include reduced activity of IFNAR2, increased activity of TYK2 and mutation of
OAS1 which means poor activation of an enzyme involved in stopping viral replication [10].
An additional finding is a gene cluster on chromosome 3 that is associated with severe
COVID-19 outcomes. COVID-19 individuals with gene variants at this locus had 1.6 odds of
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requiring hospitalisation [11]. The same study found that the susceptibility haplotype was
most strongly associated with people of Bangladeshi origin which may in part explain the
higher COVID-19 related mortality amongst Bangladeshi men compared to White males [12,
13]. It is theorised that historically, gene flow from Neanderthals in this part of the world may
have provided protection against certain pathogens through selection pressure amongst people
who live in or come from what is now known as Bangladesh, but in the case of COVID-19 it
confers a greater risk of severe infection [11]. The COVID-19 susceptibility haplotype showed
similarity to Neanderthal Vindija haplotypes [11].
The risk of infection and severity of COVID-19 is modulated by various risk factors. The
most frequently reported finding in the literature is that older patients or those with existing
respiratory or cardiovascular disease are more susceptible to severe infection.
A study found that a 60–74-year-old individual has a 5-times higher risk of hospitalisation and
90 times higher risk of death from COVID-19 compared to an 18–29-year-old [14]. Additional
studies suggest that individuals with chronic inflammatory diseases and vascular disease are also
at higher risk of adverse COVID-19 outcomes [12]. The other most significant risk factor is body
mass index (BMI) [15], which has a biological basis since obesity is associated with other condi-
tions such as heart disease and diabetes, both of which are independent risk factors. Genetic sus-
ceptibility to obesity was found in MR studies to be associated with increased risk of infection
[15]. The authors suggest that obesity could be causally linked to infection because of impaired
lung function, increased baseline adipokines and cytokines which increase risk to developing
ARDs. Additional studies support the causal relationship between obesity as a risk factor,
although some findings suggest that this relationship might be mediated by type 2 diabetes [16].
Cardiovascular disease is also a predictor of poor COVID-19 outcomes. The combination
of the hyperinflammatory environment due to a SARS-CoV-2 infection also puts the patient
into a hypercoagulable state which leads to complications such as multi-organ failure, observed
complication of severe COVID-19 [17]. Furthermore, hypertension could be a causal risk fac-
tor due to the viral spike protein binding to ACE2 receptors, thereby enhancing the activity of
the renin-angiotensin-aldosterone system which leads to inflammation and fibrosis [18]. Simi-
larly, smoking is a risk factor that has been found to increase expression of the ACE2 receptor
in the lung which provides some explanation for why smokers are more likely to require hospi-
tal admission [19].
In the present study we aim to identify traits and diseases that are related to the genetic sus-
ceptibility for COVID-19. We conducted Phenome-Wide Association Analyses to evaluate the
association of genetically determined COVID-19 susceptibility and severity using Predictive
Risk Scores (PRS) with a comprehensive set of phenotypes including disease in the UK Bio-
bank. COVID-19-related outcomes were derived from the COVID-19 Host Genetics Initiative
(https://www.covid19hg.org/).
Materials and methods
Phenome-wide association studies (PheWAS) are used to identify the effects of a trait of inter-
est across a potentially large array of available phenotypes, using a hypothesis-free approach
[20, 21]. The advantage of the hypothesis-free testing is the possible establishment of novel
associations, reporting all the results, and not only the most statistically significant ones [22].
The threshold mainly used for statistical significance is the Bonferroni correction. It is strin-
gent, since the phenotypes under investigation are considered to be independent, which is usu-
ally not the case [23]. Despite this, the large sample size used for the analysis counterweights
for the multiple testing, leading to the replication of known associations and even the discov-
ery of new ones [22].
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We used PHEnome Scan Analysis (PHESANT) [21], which is a software package for per-
forming comprehensive phenome scans in UK Biobank [24]. PHESANT tests the association
of the exposure (independent variable), in our case the PRS of COVID-19, with quantitative
and disease phenotypes in UK Biobank (dependent variables), using regression models. In
more detail, PHESANT is implemented in statistical and computing software package, R [25].
A novel rule-based algorithm is used to categorize the phenotypes and the types of regressions,
adjusted for the confounders. Based on these, the output of the software is result files depend-
ing on each test type: linear, logistic, ordered logistic and multinomial regressions. In addition,
the results include a log-file providing information about the processing flow for each field
and a model-fit-log file that shows model fit output for categorical unordered models. Lastly,
the variable-flow-counts-all file, which includes a set of counts denoting the number of vari-
ables reaching each point in the processing flow, for example whether the variable has been
analysed or has been excluded, or if some categories from the categorical fields have been
excluded, are also provided in the results. In addition, for the continuous data, the inverse nor-
mal rank transformation is used to make certain they are normally distributed. To account for
multiple testing, Bonferroni corrected threshold is calculated.
In order to assess the associations of the PRS with Hospital Episode data and data from
the General practice (GP), we used the PheWAS library [20] in R [25]. This library is used
to test the association of the exposure, the PRS of COVID-19 (independent variable),
against each one of the phecodes (dependent variables), The software uses a function to
convert the ICD-10 codes to ‘PheWAS codes’ or phecodes, which represent around 1,600
hierarchical phenotypes formed from grouped ICD-10 codes. In total, the phecodes are
divided into 17 distinct categories, such as circulatory system, endocrine/metabolic, men-
tal disorders, neurological, respiratory, plus 1 unlabelled category (denoted as NULL).
Next, binary logistic regression models are employed to examine the association of the
trait of interest with each phecode, adjusted for the confounders. For our analysis, Bonfer-
roni corrected threshold is applied.
Study population
We examined the UK Biobank, a prospective cohort of 502,504 participants, aged 37–73 years
old, recruited between 2006 and 2010. The dataset we used includes a variety of phenotypes
including blood measurement, clinical assessments, anthropometry, cognitive function, hear-
ing, arterial stiffness, hand grip strength, spirometry, ECG, data on cancer and death registries,
health and lifestyle medical conditions, operations, mental health, sociodemographic factors,
lifestyle, family history, psychosocial factors and dietary intake [22]. The analysis was per-
formed using the maximum of 379,655 White British participants, for the variables that had
no missing values.
In the present analysis, as trait of interest (exposure) we used the PRS of COVID-19. The
PRS is created based on the unweighted sum of increasing risk COVID-19 alleles an individual
carries, based on data from the HGI COVID-19 GWAS [26].
For our analysis we used summary statistics from the A2, B2 and C2 analyses. For A2 analy-
sis the phenotype is defined as “Very severe respiratory confirmed COVID-19 vs. population”.
For analysis B2, the phenotype is defined as “Hospitalized COVID-19 vs. population”. For the
C2 analysis the phenotype is defined as “COVID-19 vs. population”. Our analyses were
focused on individuals of European ancestry (White British).
A higher allele score corresponds to more severe COVID-19, depending on the definition
used for the GWAS meta-analysis defined above, and it is standardized to have mean of 0 and
standard deviation of 1.
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SNP selection for the PRS
We used conditional and joint analysis (GCTA-COJO) [27, 28], is employed to select the
COVID-19-associated Single Nucleotide Polymorphisms—SNPs for the PRS. A stepwise pro-
cedure is used for SNP selection and the joint effects of all selected SNPs are estimated after
the model has been optimized. These SNPs are still genome-wide significant, independent and
the variance explained by them is larger than considering only the leading SNP at each locus.
In more detail, conditional analysis was performed using 50,000 unrelated and randomly sam-
pled European participants from UK Biobank as LD reference. We performed analyses using
P-value at p = 5�10−8 to declare a genome-wide significant hit. Also, SNPs having allele fre-
quency differences larger than 0.2, were excluded from the analysis along with SNPs having
MAF� 0.001. As adjustments we used age at recruitment, sex, genotype batch, to account for
the model variability. We also adjusted for the first 15 genetic principal components PCs to
control for confounding via population stratification.
The number of SNPs reported from each analysis are presented in Table 1.
Phenotypes
We used phenotypic data from the UK Biobank including data from Hospital Episode Statis-
tics (HES) and General Practice (GP). HES is a database containing details of all admissions at
NHS hospitals in England. All clinical data are coded using International Classification of Dis-
ease (ICD) codes and all operations and procedures are coded using the Office of Population
Censuses and Surveys (OPCS); Classification of Surgical Operations and Procedures (4th revi-
sion). The most recent ones are ICD-10, which are the ones we used, including 11,726 unique
ICD-10 codes for 410,321 unique participants.
GP data contain the vast majority of a person’s health care information; 40% of GP records
are linked to UK Biobank cohort up to now. Multiple clinical coding data are provided using
Read codes; a standard vocabulary for clinicians to record patient findings and procedures.
The most recent is version 3 CTV3 or Read v3), which is the one we used. Regarding the par-
ticipants, 999 were excluded because the clinical event or prescription date precedes partici-
pant date of birth and 66 were removed because the event date is a date in the future and is
presumed to be a place-holder or other system default) [29]. However, the 80,982 unique Read
v3 codes, were converted to ICD-10 codes [30], in order to be subsequently used from the Phe-
WAS library [20] in R [25]. As a result, 9,492 unique ICD-10 codes for 161,333 unique
participants.
Results and discussion
PheWAS analyses were conducted to evaluate the effect of genetically determined risk for
three COVID-19 outcomes, severe, hospitalised and general COVID-19 infection (see Meth-
ods), on a comprehensive set of phenotypes including disease in UK Biobank.
Severe respiratory confirmed COVID-19 vs. population (A2) PRS was significantly associ-
ated with increased levels of lymphocytes for both counts and percentage (beta = 0.013,
Table 1. Analysis and the corresponding number of SNPs used in the PRS.
Analysis Number of SNPs from COJO analysis–p<5�10−8
Very severe respiratory confirmed COVID-19 vs. population–
A2
11
Hospitalized COVID-19 vs. population–B2 9
COVID-19 vs. population–C2 5
https://doi.org/10.1371/journal.pone.0256988.t001
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P = 3.15e-15; beta = 0.01, p = 5.6 e-10), respectively. Furthermore, the PRS was associated with
decreased levels of platelet count (beta = -0.008, p = 2.6e-07). Severe COVID-19 outcome cap-
tured by the genetic score was associated with lower sex hormone binding globulin (SHBG)
(beta = -0.0075, p = 2.59e-06), as well as with decreased FEV1/FVC ratio (beta = -0.009, p = 1.8
e-06). In addition, severe COVID-19 was associated with lower levels of insulin like growth fac-
tor-1 (IGF-1) (beta = -0.010, P = 3.2e-10) as shown in Fig 1. For the HES data, none of the phe-
notypes passed the Bonferroni correction threshold of statistical significance (p = 3.35e-05);
most significant associations were with hemopoietic traits especially congenital coagulation
defects (OR = 0.85, p = 2.68 e-04). Similarly, for the GP data, none of the phenotypes passed the
Bonferroni test.
Hospitalized COVID-19 vs. population PRS was associated with decreased levels of platelets
counts (beta = -0.01, P = 1.2 e-08), and with increased lymphocyte counts (beta = 0.007,
p = 8.19e-06). Furthermore, we observed an association with decreased FEV1/FVC ratio (beta
= -0.01, P = 1.4e-08) and increased body fat percentage (beta = 0.0057, p = 2.6 e-06), especially
with increased arms and trunk fat mass and percentages (beta = 0.003, p = 1.56 e-06), and
decreased standing height (beta = -0.006, p = 3.85 e-07), and sitting height (beta = -0.006,
p = 3.38e-07) (Fig 2). No association signal passed Bonferroni correction in neither the HES
nor GP data analysis.
The general COVID-19 infection vs population (C2) PRS was associated with lower levels
of alkaline phosphate (beta = -0.084, p<2.23 e-308) and aspartate aminotransferase (beta =
-0.01, p = 4.32e-09). Contrary to aspartate aminotransferase, a positive association was found
with alanine aminotransferase (beta = 0.01, p = 9.41 e-12).
Finally, as shown in Fig 3, several haematological traits showed a significant association
including lower levels of monocyte counts (beta = -0.02, p = 1.81e-31), RBC cells (beta = -0.01
p = 1.25e-14), neutrophils (beta = -0.01, p = 1.8e-10) and lymphocytes (beta = 0.01, p = 6.68e-09).
Moreover, we identified significant signals between COVID-19 susceptibility with blood clots
in the leg (OR = 1.1, p = 1.66e-16) and with increased risk for blood clots in the lung
(OR = 1.12, p = 1.45 e-10).
Fig 1. Forest plot of PheWAS analyses of severe COVID-19 risk.
https://doi.org/10.1371/journal.pone.0256988.g001
Fig 2. Forest plot of PheWAS analyses of hospitalised COVID-19 risk.
https://doi.org/10.1371/journal.pone.0256988.g002
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For the HES data, COVID-19 risk was associated with disorders of circulatory system were
(OR = 1.04, p = 1.31e-09) (Fig 4). Furthermore, in the GP data, COVID-19 risk was shown to
be associated with increased risk for phlebitis and thrombophlebitis (OR = 1.11, p = 5.36e-08),
phlebitis and thrombophlebitis of lower extremities (OR = 1.15, p = 3.43e-05) (Fig 5). Full
results for all the analyses are provided in S1 Table.
Fig 3. Forest plot of Phewas analyses of general COVID-19 susceptibility.
https://doi.org/10.1371/journal.pone.0256988.g003
Fig 4. PheWAS associations for COVID-19 susceptibility in HES data.
https://doi.org/10.1371/journal.pone.0256988.g004
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Our PheWAS analyses in UK Biobank identified a spectrum of associations between both
genetically determined COVID-19 susceptibility and severity and a number of traits. Severe
COVID-19 outcome was associated with increased counts and percentages of lymphocytes.
However, several studies have also reported an association of lymphopenia with COVID-19
severity, in accordance with our findings for general COVID-19 susceptibility [31]. Lympho-
penia is rarely observed in children infected with COVID-19, a group in which mortality rate
is very low. Lymphocytes are known to play a crucial role in viral infections. Furthermore,
atypical reactive lymphocytes are present in COVID-19 patients with better prognosis [32].
However, additional studies are needed to fully delineate the pathophysiology of immunologi-
cal cells contribution to the disease.
Severe COVID-19 risk was associated with lower platelet count, in agreement with meta-
analytic studies [33]. Thrombocytopenia has been shown to be common in severe cases of
COVID-19 during infection, proposing it as a clinical indicator for illness progression during
hospitalisation [34]. Those who are severely affected have shown coagulation abnormalities
and clotting complications such as microvascular events, which have been commonly reported
in retrieved tissues from severe cases [35]. Furthermore, the presence of platelet aggregates
and macro-thrombocytes have been associated with COVID-19 patients admitted to ICU [36].
In a study conducted by Manne et al. [37], they reported an increased expression of platelet
genes resulting in an increased activation and aggregation in patients infected by coronavirus
reflecting their hyperactive status [37].
SARS-CoV-2 has been associated with abnormal pulmonary function, mainly by causing
severe acute respiratory syndrome and being a significant reason for mortality and hospitalisa-
tion [38]. In this study, increased risk of severe COVID-19 and hospitalisation were associated
with decreased FEV/FVC z-score. Additionally, studies have noted post-recovery changes
resembling restrictive pulmonary diseases and variations in resorting to normal range levels
[39, 40].
We also observed that genetically determined severe COVID-19 was associated with lower
levels of IGF-1. Fan et al. (2021) suggested that a higher concentration of IGF-1 has an associa-
tion with a lower risk of the mortality of COVID-19 [41]. Although IGF-1 role in severe
Fig 5. PheWAS associations for COVID-19 susceptibility in GP data.
https://doi.org/10.1371/journal.pone.0256988.g005
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respiratory distress has not been fully delineated, further research and understanding of its
pathway and contribution shows potential as a therapeutic mean. Severe COVID-19 risk was
associated with decreased levels of SHBG. SHBG has a major role in balancing testosterone
levels as it has a greater affinity for it more than oestrogen [42]. Interestingly, most male ICU
admitted patients with COVID-19 had shown lower testosterone levels, deeming it a screening
parameter for early detection of high-risk patients [43, 44]. Nevertheless, current studies lack
describing the role of sex hormones and their binding proteins in COVID-19.
The risk of COVID-19 hospitalisation risk outcome was associated with increased trunk
and arms fat mass and lower standing and sitting height. Several studies have shown that most
hospitalised COVID-19 patients are obese [45]. Furthermore, severe outcome of COVID-19
has been associated with high visceral fat adiposity in European adults [46]. Obesity is identi-
fied as abnormal secretions of cytokines and adipokines resulting in increased inflammation;
thus, it might contribute to the outcomes requiring hospitalization [47, 48]. Although abnor-
mal liver enzymes were noted in the majority of COVID-19 patients, studies were not conclu-
sive on the significance of liver function enzymes being informative predictors of the severity
of the disease progression [49, 50].
For general COVID-19 susceptibility, we observed significant associations with increased
phlebitis and thrombophlebitis. This result is in agreement with the available meta-analytic lit-
erature as COVID-19 procoagulant activity such as deep vein thrombosis, pulmonary embo-
lism, and superficial phlebitis, are prevalent in moderate to severe cases [51]. Furthermore, we
identify significant association of general COVID-19 with increased blood clot events in leg
and lungs. In a meta-analytic study blood clots rates of COVID-19 have shown to be a risk of
mortality [52].
The reported associations between both genetically determined COVID-19 susceptibility
and severity and other diseases adds to the identification and stratification of individuals at
increased risk, including those undergoing anti-inflammatory therapy [53]. Further work will
be required to better understand the biological and clinical value of these findings including
long-term complications after infection.
Conclusions
We conducted Phenome-Wide Association Analyses to evaluate the association between
genetically determined COVID-19 susceptibility and severity with a comprehensive set of phe-
notypes and diseases in the UK Biobank. Our study identifies significant associations of geneti-
cally determined COVID-19 susceptibility with increased blood clot events in leg and lungs,
thrombophlebitis and circulatory diseases.
Supporting information
S1 Table. Full PheWAs results.
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